AP Biosciences Company Description
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs.
It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors.
The company was founded in 2013 and is based in Taipei City, Taiwan.
Country | Taiwan |
Founded | 2013 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 37 |
CEO | Jeng-Horng Her |
Contact Details
Address: No. 508, Zhongxiao East Road Taipei City, 115 Taiwan | |
Phone | 886 2 2653 2886 |
Website | apbioinc.com |
Stock Details
Ticker Symbol | 6945 |
Exchange | Taipei Exchange |
Fiscal Year | January - December |
Reporting Currency | TWD |
ISIN Number | TW0006945009 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Jeng-Horng Her | Chief Executive Officer |
Tony Lin | Chief Financial Officer |